ProCE Banner Activity

CE / CME

Nursing Considerations for Managing Patients with Hemophilia A: Conversation Between a Hematologist and a Nurse Practitioner

Multimedia
In this interactive presentation, learn how nurses play key roles in transitioning care and promoting self-management in patients with hemophilia A.

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Nurses: 0.50 Nursing contact hour

Released: April 11, 2022

Expiration: April 10, 2023

No longer available for credit.

Share

Faculty

Glaivy Batsuli

Glaivy Batsuli, MD

Assistant Professor of Pediatrics
Pediatric Hematologist
Division of Pediatric Hematology and Oncology
Department of Pediatrics
Emory University
Pediatric Hematologist
Pediatric Hematology and Oncology
Aflac Cancer and Blood Disorders Center of Childrens Healthcare of Atlanta
Atlanta, Georgia

Kelly Tickle

Kelly Tickle, MSN, APN, PCNS-BC, PPCNP-BC

Pediatric Nurse Practitioner/Nurse Scientist
Hemophilia of Georgia Center for Bleeding and Clotting Disorders
AFLAC Cancer and Blood Disorders Center at Children’s Healthcare of Atlanta
Atlanta, Georgia

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Genentech, a member of the Roche Group

Partners

NHF

ProCE Banner

Target Audience

This educational program is intended for all healthcare professionals across multiple disciplines and specialties who care for patients with hemophilia A, including hematologists, nurse practitioners, pharmacists/managed care professionals, surgeons, pathologists, and social workers/mental health professionals.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Equip adolescents/young adults and other appropriate patients with hemophilia A, through counseling and education, to assume autonomous care for much of their hemophilia prophylaxis

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Glaivy Batsuli, MD

Assistant Professor of Pediatrics
Pediatric Hematologist
Division of Pediatric Hematology and Oncology
Department of Pediatrics
Emory University
Pediatric Hematologist
Pediatric Hematology and Oncology
Aflac Cancer and Blood Disorders Center of Childrens Healthcare of Atlanta
Atlanta, Georgia

Glaivy Batsuli, MD, has disclosed that she has received consultant/advisor/speaker fees from Bio Products Laboratories and Kedrion.

Kelly Tickle, MSN, APN, PCNS-BC, PPCNP-BC

Pediatric Nurse Practitioner/Nurse Scientist
Hemophilia of Georgia Center for Bleeding and Clotting Disorders
AFLAC Cancer and Blood Disorders Center at Children’s Healthcare of Atlanta
Atlanta, Georgia

Kelly Tickle, MSN, APN, PCNS-BC, PPCNP-BC, has disclosed that she has received funds for research from the National Hemophilia Foundation and is a Dudley Nursing Research Fund.

Staff Disclosure

Staff

Kelly Brandt, PharmD

Kelly Brandt, PharmD, has no relevant conflicts of interest to report.

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Kristen Morrow, PhD

Editorial Contributor

Kristen Morrow, PhD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen M. Rosenthal, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category I Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.

Credit Designation

CCO designates this continuing education activity for 0.5 contact hours (.05 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-103-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 11, 2022, through April 10, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this program is to improve the knowledge, competence, and performance of healthcare professionals involved in the management of patients with hemophilia A, in the benefits of prophylaxis therapy and adherence to treatment regimens for patients with hemophilia A.